Inspire Investing LLC Reduces Stock Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Inspire Investing LLC cut its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 17.2% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 57,550 shares of the biotechnology company’s stock after selling 11,916 shares during the quarter. Inspire Investing LLC’s holdings in BioCryst Pharmaceuticals were worth $356,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in BCRX. Vanguard Group Inc. boosted its stake in BioCryst Pharmaceuticals by 15.4% in the 4th quarter. Vanguard Group Inc. now owns 17,763,720 shares of the biotechnology company’s stock worth $106,405,000 after purchasing an additional 2,371,401 shares during the period. Avoro Capital Advisors LLC lifted its holdings in shares of BioCryst Pharmaceuticals by 13.0% in the fourth quarter. Avoro Capital Advisors LLC now owns 13,050,000 shares of the biotechnology company’s stock worth $78,170,000 after buying an additional 1,500,000 shares in the last quarter. Kynam Capital Management LP boosted its position in shares of BioCryst Pharmaceuticals by 41.9% in the first quarter. Kynam Capital Management LP now owns 6,527,491 shares of the biotechnology company’s stock valued at $33,160,000 after acquiring an additional 1,927,491 shares during the period. Braidwell LP boosted its position in shares of BioCryst Pharmaceuticals by 6.6% in the fourth quarter. Braidwell LP now owns 5,718,477 shares of the biotechnology company’s stock valued at $34,254,000 after acquiring an additional 355,497 shares during the period. Finally, Norges Bank purchased a new position in BioCryst Pharmaceuticals during the fourth quarter valued at approximately $13,278,000. 85.88% of the stock is currently owned by institutional investors.

BioCryst Pharmaceuticals Trading Down 0.5 %

Shares of NASDAQ BCRX opened at $8.11 on Friday. The stock’s 50-day moving average is $7.79 and its 200 day moving average is $6.35. The stock has a market cap of $1.67 billion, a price-to-earnings ratio of -7.58 and a beta of 1.88. BioCryst Pharmaceuticals, Inc. has a 1-year low of $4.03 and a 1-year high of $8.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.11. The business had revenue of $109.30 million during the quarter, compared to the consensus estimate of $98.30 million. During the same quarter in the previous year, the firm posted ($0.24) earnings per share. The company’s revenue was up 34.9% compared to the same quarter last year. On average, analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.45 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Amy E. Mckee sold 8,600 shares of BioCryst Pharmaceuticals stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $6.32, for a total value of $54,352.00. Following the transaction, the director now owns 27,831 shares in the company, valued at $175,891.92. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 4.80% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several analysts have issued reports on the stock. JMP Securities increased their target price on shares of BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the stock a “market outperform” rating in a research note on Tuesday, August 6th. HC Wainwright reissued a “buy” rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 6th. StockNews.com raised BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, August 6th. Barclays boosted their price objective on BioCryst Pharmaceuticals from $6.00 to $7.00 and gave the stock an “equal weight” rating in a report on Tuesday, August 6th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $10.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 6th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $14.17.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.